Application and Efficacy Evaluation of a Modified Ostomy Appliance in Managing Peristomal Irritant Contact Dermatitis: A Randomised Controlled Trial
International Wound Journal · 2025
DOI: 10.1111/iwj.70794 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Wound Journal, 2025. Verfasst von Xiaoxiao Ying und 3 weiteren Autor:innen. Beteiligte Einrichtung: Ostomy Nursing Clinics, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, China. Hauptthemen laut MEDLINE: Dermatitis, Irritant, Wound Healing, Ostomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhejiang Provincial Medical and Health Science and Technology Program Project, Xuzhou Medical University Affiliated Hospital Development Fund Excellent Talent Fund Project.
Abstract (Originalsprache)
Irritant contact dermatitis is a common peristomal skin complication. Due to the continuous irritation from intestinal fluids and faeces, the healing of this dermatitis is slow and the condition severely impairs patients' quality of life. The study aimed to evaluate the efficacy of a modified insertable ostomy appliance in promoting healing and improving patient outcomes. A randomised controlled trial was conducted from January 2022 to December 2024 in a tertiary hospital. The enrolled patients, all diagnosed with irritant contact dermatitis, were randomly assigned to two groups. The control group wore the conventional two‐piece ostomy appliance, while the experimental group wore the modified insertable ostomy appliance. Outcomes were assessed on Days 3, 7, 14 and 28. The primary outcome was the healing rate (Discoloration, Erosion and Tissue overgrowth [DET] score ≤ 2) at Day 28. Secondary outcomes included the DET score, Visual Analogue Scale (VAS) pain score, Stoma Quality of Life questionnaire (Stoma‐QOL) score and the incidence of appliance leakage. A total of 89 eligible participants completed the trial. The experimental group showed a significantly higher 28‐day healing rate (73.3% vs. 29.5%, p < 0.001), lower DET scores (Day 28: 2.0 vs. 4.5, p < 0.001), reduced VAS scores (Day 28: 1.5 vs. 2.0, p < 0.001), higher Stoma‐QOL scores (Day 28: 55.67 vs. 51.64, p < 0.001) and lower leakage rate (13.3% vs. 93.2%, p < 0.001). The modified ostomy appliance significantly improves healing, reduces pain and enhances quality of life, representing a novel solution for clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ostomy Nursing Clinics, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
- Department of Anorectal Surgery, Southeast University Affiliated Xuzhou Central Hospital, Xuzhou, China.
- Department of Colorectal Surgery, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
ORCID-Profile: Chan Xu
Förderung
- Zhejiang Provincial Medical and Health Science and Technology Program Project
- Xuzhou Medical University Affiliated Hospital Development Fund Excellent Talent Fund Project
Zitieren
APA
Ying, X., Huang, L., Yu, F., & Xu, C. (2025). Application and Efficacy Evaluation of a Modified Ostomy Appliance in Managing Peristomal Irritant Contact Dermatitis: A Randomised Controlled Trial. International Wound Journal. https://doi.org/10.1111/iwj.70794
Vancouver
Ying X, Huang L, Yu F, Xu C. Application and Efficacy Evaluation of a Modified Ostomy Appliance in Managing Peristomal Irritant Contact Dermatitis: A Randomised Controlled Trial. International Wound Journal. 2025. doi:10.1111/iwj.70794
BibTeX
@article{Ying2025,
author = {Ying, Xiaoxiao and Huang, Luqiao and Yu, Feng and Xu, Chan},
title = {Application and Efficacy Evaluation of a Modified Ostomy Appliance in Managing Peristomal Irritant Contact Dermatitis: A Randomised Controlled Trial},
journal = {International Wound Journal},
year = {2025},
doi = {10.1111/iwj.70794}
}
EUVIMED